Citadel Advisors
EWTX icon

Citadel Advisors’s Edgewise Therapeutics EWTX Stock Holding History

Citadel Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$318K Sell
10,100
-63,400
-86% -$1.83M ﹤0.01% 10342
2025
Q4 		$1.82M Buy
73,500
+27,400
+59% +$550K ﹤0.01% 6113
2025
Q3 		$748K Buy
46,100
+8,100
+21% +$115K ﹤0.01% 8187
2025
Q2 		$498K Sell
38,000
-12,600
-25% -$182K ﹤0.01% 8644
2025
Q1 		$1.11M Buy
50,600
+10,400
+26% +$273K ﹤0.01% 6725
2024
Q4 		$1.07M Sell
40,200
-29,800
-43% -$949K ﹤0.01% 6861
2024
Q3 		$1.87M Buy
70,000
+59,100
+542% +$1.18M ﹤0.01% 5666
2024
Q2 		$196K Sell
10,900
-3,800
-26% -$66.3K ﹤0.01% 9973
2024
Q1 		$268K Buy
14,700
+10,100
+220% +$161K ﹤0.01% 9716
2023
Q4 		$50.3K Buy
4,600
+3,500
+318% +$24.6K ﹤0.01% 11777
2023
Q3 		$6.3K Buy
1,100
+100
+10% +$680 ﹤0.01% 13325
2023
Q2 		$7.75K Sell
1,000
-600
-38% -$5.06K ﹤0.01% 13356
2023
Q1 		$10.7K Sell
1,600
-1,200
-43% -$11.1K ﹤0.01% 13514
2022
Q4 		$25K Buy
+2,800
New +$26.3K ﹤0.01% 12942

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Citadel Advisors's EWTX Position: Q1 2026 in Review

Citadel Advisors increased its Edgewise Therapeutics (EWTX) stake by 249% in Q1 2026, buying an estimated $8.82M and bringing the position to 429,032 shares worth $13.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2823.

Citadel Advisors first reported a position in EWTX in Q1 2021 and has held it in 21 quarters since. The position peaked at $77.4M in Q1 2021. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Citadel Advisors held 429,032 shares of Edgewise Therapeutics worth $13.5M as of Q1 2026.
  • Citadel Advisors bought 305,935 Edgewise Therapeutics shares in Q1 2026, an estimated $8.82M.
  • Edgewise Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2823 holding.
  • Citadel Advisors first reported a position in Edgewise Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Citadel Advisors's Edgewise Therapeutics position peaked at $77.4M in Q1 2021.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.